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Abstract
Background: Despite effective treatments and long-standing management guidelines, there are approximately
1400 hospital admissions for asthma weekly in the United Kingdom (UK), many of which could be avoided. In our
previous research, a secondary analysis of the intervention (ARRISA) suggested an improvement in the
management of at-risk asthma patients in primary care. ARRISA involved identifying individuals at risk of adverse
asthma events, flagging their electronic health records, training practice staff to develop and implement practice-
wide processes of care when alerted by the flag, plus motivational reminders. We now seek to determine the
effectiveness and cost-effectiveness of ARRISA in reducing asthma-related crisis events.
Methods: We are undertaking a pragmatic, two-arm, multicentre, cluster randomised controlled trial, plus health
economic and process evaluation. We will randomise 270 primary care practices from throughout the UK covering
over 10,000 registered patients with ‘at-risk asthma’ identified according to a validated algorithm. Staff in practices
randomised to the intervention will complete two 45-min eLearning modules (an individually completed module
giving background to ARRISA and a group-completed module to develop practice-wide pathways of care) plus a
30-min webinar with other practices. On completion of training at-risk patients’ records will be coded so that a flag
appears whenever their record is accessed. Practices will receive a phone call at 4 weeks and a reminder video at
6 weeks and 6 months. Control practices will continue to provide usual care. We will extract anonymised routine
patient data from primary care records (with linkage to secondary care data) to determine the percentage of at-risk
patients with an asthma-related crisis event (accident and emergency attendances, hospitalisations and deaths)
after 12 months (primary outcome). We will also capture the time to crisis event, all-cause hospitalisations, asthma
control and any changes in practice asthma management for at-risk and all patients with asthma. Cost-effectiveness
analysis and mixed-methods process evaluations will also be conducted.
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Discussion: This study is novel in terms of using a practice-wide intervention to target and engage with patients at
risk from their asthma and is innovative in the use of routinely captured data with record linkage to obtain trial
outcomes.
Trial registration: ISRCTN95472706. Registered on 5 December 2014.
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Background
Worldwide, asthma affects 334 million people [1]. In the
UK, which has one of the highest prevalence rates in
Europe, there are 5.4 million patients with asthma, and
asthma affects one in five households [2]. A quarter of
all asthma patients have poor symptom control [3] and
185 people are admitted to hospital because of asthma
attacks every day in the UK [2]. Asthma attacks result in
major social, psychological and healthcare costs. For ex-
ample, attacks are associated with a doubling of the health-
care costs for managing severe asthma in both children
and adults [4, 5]. Asthma is, therefore, a common condi-
tion which results in a large, unnecessary personal, health-
care and economic burden [6]. Worryingly, given that
there are an increasing number of effective treatments and
long-standing, evidence-based management guidelines for
asthma [7], the death rate for asthma has not reduced over
recent years [8].
It is widely accepted that the majority of deaths and hos-
pital admissions from asthma are associated with prevent-
able factors [9]. In 2012, this prompted a National Review
of Asthma Deaths (NRAD) [10], which showed that poor
access to care and poor adherence with preventive medi-
cation(s) were key contributors in the deaths of a large
proportion of patients. Patient-assessed poor access to
primary care is also associated with emergency hospital
admissions for asthma [11]. Unfortunately, due to compli-
cating clinical and psychosocial characteristics, patients
with asthma who are at particular risk of attacks (at-risk
asthma) often fail to attend routine appointments or
engage in initiatives [12], such as self-management educa-
tion, that improve outcomes in general asthma popula-
tions [13]. In addition, these patients characteristically
under-use primary care services, often fail to attend sched-
uled appointments [14, 15] and have difficulty adhering to
treatments [16, 17]. It is these same patient groups that
are also most often excluded from clinical trials. Existing
evidence is thus unlikely to be generalisable [18] and re-
search is urgently needed to identify better management
strategies for this group. Systematic nationwide training
and implementation programmes, mostly based in pri-
mary care, are able to reduce the morbidity and impact of
asthma with reduced costs [19]. Also, a clinical care path-
way for children with asthma has been shown to modify
practice behaviour and reduce emergency department
attendance and hospitalisations, but not significantly so,
compared to usual care [20]. Indeed, the current British
Thoracic Society/Scottish Intercollegiate Guideline Net-
work (BTS/SIGN) British guideline on the management of
asthma notes that ‘well-conducted studies are needed to
define the benefits of care pathways for asthma. These
should include large, suitably powered studies to clarify
the impact of pathways promoting systematic management
of people with high-risk asthma in UK primary care’. [7]
In an observational pilot study at a single primary care
practice [21], electronic flagging of the electronic health
records (EHRs) of 26 patients, demonstrating character-
istics previously associated with adverse asthma out-
comes, and training all practice staff in appropriate
actions to take on seeing the flag was associated with a
reduction in the number of emergency events for asthma
in these individuals over 1 year, compared to 26 age-,
sex- and treatment-matched controls. Our subsequent
regional cluster randomised trial involving 29 primary
care practices in Norfolk [22] covering 911 people at a
high-risk of experiencing asthma crisis events (at-risk
asthma, defined in line with contemporaneous guide-
lines as severe asthma plus adverse psychosocial fac-
tors) similarly flagged patients’ EHRs and delivered a
1-h practice-based training session for practice staff.
The intervention did not reduce the primary composite
endpoint of asthma attacks [23, 24] over 1 year. How-
ever, increases in the number of prescriptions of pred-
nisolone (31% (95% confidence interval (CI) − 8 to 85))
masked reductions in the percentage of hospitalisations
(50% (95% CI 6 to 74)) and accident and emergency
(A&E) attendances (26% (95% CI − 31 to 58) amongst
patients in intervention versus control practices. The
intervention was well received by practice staff (accord-
ing to an exit questionnaire) and resulted in an esti-
mated cost-saving of £138.21 (95% CI £1248 to − £910)
per patient in the intervention arm.
This regional study suggested that our primary care
intervention for at-risk asthma patients (ARRISA) may
have potential as a strategy for improving practice-level
management and reducing emergency admissions, near-
fatal asthma and asthma deaths, in this group. However,
it remains to be seen whether these findings would trans-
late into a meaningful clinical benefit at a larger scale.
Furthermore, the identification of at-risk individuals in the
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previous studies was achieved by manually searching re-
cords to provide evidence of adverse psychosocial factors
and the training was undertaken via a face-to-face,
practice-based group discussion led by an experienced
facilitator. These features of the intervention would be dif-
ficult to roll out nationally so we modified these processes
in our current study: individuals with at-risk asthma will
be automatically identified using a computer code con-
taining details of an algorithm based on data routinely
available in primary care EHRs and the training will be de-
livered via an online eLearning platform and webinars.
Furthermore, in contrast to the original study where out-
come data were obtained by semi-manually searching the
primary care EHRs, in the current study we will utilise an-
onymous data extraction and record linkage of primary
and secondary care records.
The study aims to test the hypothesis that systematic-
ally identifying patients at risk of severe exacerbations of
asthma, flagging their primary care EHR to provide en-
during prompts at the time of contacts with the practice,
training all practice staff about the systematic manage-
ment of these patients and providing on-going practice
support (hereafter referred to as creation and integration
of a primary care at-risk asthma register) will reduce cri-
sis asthma events (asthma-related deaths, hospitalisa-
tions and A&E attendances) for at-risk patients and be
clinically acceptable and cost-effective without detriment
to the care of non-at-risk asthma patients.
Our intervention operates at the practice level. A clus-
ter randomised trial design is, therefore, appropriate
with the general practice as the unit of randomisation.
As such, although the majority of objectives (including
primary endpoint) and the health economic analysis per-
tain to the participant level, some objectives pertain to
the cluster level (including aspects of the process evalu-
ation). The study will be conducted in a controlled open
study with blind assessment. The comparator will be
usual care as defined by the current BTS/SIGN British
Asthma Guideline [7] and National Institute for Health
and Care Excellence (NICE) guidelines [25].
Methods
Aims
The primary aim of this study is to determine whether
the creation and integration of at-risk asthma registers
into primary care, as conceptualised in our ’At-Risk
Registers Integrated into primary care to Stop Asthma
crises’ (ARRISA) intervention, reduces asthma-related
crisis events (A&E attendances, hospitalisations and
deaths) for at-risk patients over a 12-month period com-
pared to control practices. Our secondary aims are to as-
sess outcomes (time to first crisis event, asthma control,
all-cause admission or death) for all patients with
asthma; and also to examine changes in the processes of
asthma care (treatments, vaccinations, use of action plans
or smoking cessation services, adherence to treatment)
within practices. We also aim to assess whether this inter-
vention is acceptable to healthcare professionals and pa-
tients and cost-effective from the perspective of the
National Health Service (NHS). We will identify character-
istics that influence uptake, integration and effectiveness of
the intervention and explore causal mechanisms leading to
changes in outcomes, including any unanticipated effects.
Trial design
This is a two-arm, pragmatic, multicentre, cluster rando-
mised controlled trial plus health economic and process
evaluation comparing usual care (control) to a complex,
primary care practice-level intervention comprising: (1)
creation of an asthma at-risk register, (2) online eLearn-
ing training for practice staff, (3) Computerised Decision
Support System (CDSS) involving flagging of at-risk pa-
tients’ records to prompt agreed actions and (4) ongoing
practice support. The intervention targets all healthcare
professionals and reception staff within practices. The
trial outline is shown in Fig. 1 and the schedule of enrol-
ment, interventions and assessments is shown in Fig. 2.
The trial protocol (v1.3, dated 23 March 2018) is based
on the Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) 2013 Statement for proto-
cols of clinical trials (see Additional file 1).
Routinely available data from patient records on out-
comes, processes of care and healthcare use will be
captured anonymously, without the involvement of the
practice, at the end of the 12-month study period. Add-
itional resource use data, for the purposes of economic
evaluation, will be captured during the online training, post
training and 12-month questionnaires. Data from a baseline
practice demographic survey, the training software, ques-
tionnaires completed post training and at 12 months, plus
focus groups and individual interviews undertaken with a
sub-sample of practice staff and patients towards the end of
the study, including those from the whole asthma popula-
tion and those with at-risk asthma in the intervention and
control groups (see below), will contribute to the process
evaluation. This will take a mixed-methods sequential
explanatory approach to exploring implementation, mecha-
nisms and contextual influences on the intervention.
Setting
The setting is primary care practices within the UK, with
health economic analysis from the perspective of the NHS.
Participants
Clusters – Primary care practices
Recruitment
Primary care practices are being identified via the National
Institute for Health Research (NIHR) Clinical Research
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Networks (CRN), Health and Care Research Wales, the
Scottish Primary Care Research Network (SPCRN) and
respiratory charities, societies and networks. The regions
involved are: East Midlands, Eastern, Greater Manchester,
Kent Surrey and Sussex, North East and North Cumbria,
North Thames, North West Coast, North West London,
South West Peninsula, Thames Valley and South Midlands,
Wessex, West Midlands, West of England, Yorkshire and
Humber in England, plus Scotland and Wales. Practices
are selected by purposive sampling to ensure adequate rep-
resentation from the devolved nations, from urban versus
rural areas, and using different general practitioner (GP)
software systems. All practices complete an online practice
questionnaire as part of the recruitment process to check
eligibility before randomisation and to provide stratification
information and demographic data.
Inclusion criteria
Primary care practices in the UK.
Exclusion criteria
1. Practices already implementing a formal, prospective
process for identification of patients with at-risk asthma
and practice-wide targeting of asthma care on every con-
tact with a patient or their record
2. Practices hosting or affected by research, or
other aspects of care, which might significantly influ-
ence the practice wide process of care for patients
with ‘at-risk’ asthma, or the ability to complete the
study as planned; including incompatible practice
software
Where decisions based on these criteria are not
clear-cut, information about the practice circum-
stances is collected by the research team and a deci-
sion on eligibility taken by a panel of investigators
(AW, HP, MN).
Individual patients
Patients at recruited practices are included in the study
if they have at-risk asthma as determined by our algo-
rithm applied to routinely available primary care data
forming the ‘original register’. Practice staff may add or
remove patients from the register (see below), but the
primary analysis will be conducted using data from all
patients on the original register without additions or
withdrawals. In addition, data from all patients with
Fig. 1 ARRISA-UK trial outline
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asthma defined on the basis of being on the practice
asthma register will be included for the purpose of
examining secondary outcomes.
Patients will be excluded if they have refused for their
anonymous data to be used in research or are terminally
ill and receiving palliative care. Patients have the right to
refuse access to their data at any point until the conclu-
sion of the data extraction.
Process evaluation
Inclusion
As well as cluster- and patient-level data as above, for
the purposes of the process evaluation selected practice
staff and patients at participating practices will be
approached to be involved in focus groups and/or quali-
tative interviews.
Exclusion
Individuals of under 16 years of age, unable to com-
municate in English or give informed consent will be
excluded from focus groups and interviews.
Intervention
This is a practice-wide (cluster-level) complex interven-
tion comprising four main components:
1. Establishment of a practice at-risk asthma register:
We have developed and validated an algorithm, using
routinely collected primary care data, for identifying
those patients most at risk of attending A&E, being
admitted to hospital or dying from an asthma attack.
Factors in the algorithm include previous exacerbation
history, coding for anxiety or depression, smoking
history and prescribing data and laboratory results.
Automated electronic searches identify patients with
at-risk asthma from practice-based data using this al-
gorithm. This is a two-stage process with the initial
generation of an anonymised list and then coding to
provide the names and details of the patients. Pro-
grammes and instructions for searches, with fre-
quently asked questions, for the specific computer
software programme of each practice will be sent to
the information technology (IT) lead at the practice
by email or compact disc (CD).
Fig. 2 ARRISA-UK schedule of enrolment, interventions and assessments
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A representative (usually asthma GP lead or asthma
nurse) at each intervention practice receives a document
by email which explains ‘at-risk asthma’ and gives instruc-
tions on how to modify the list of patients with their re-
cords flagged (see CDSS below). GPs and asthma nurses
are able to review the computer-generated list of at-risk
patients, and exceptionally, with documented justification
of the change, delete any who should not be on the list
(e.g. receiving palliative care) and identify any other
‘at-risk’ patients known to them. They may modify the list,
as above, for the duration of the study although the pri-
mary analysis will be based on data from patients included
in the original register prior to modifications
2. Practice-wide, online training (eLearning)
We have developed an innovative multi-component
practice-wide intervention based on the material delivered
in the face-to-face training developed for the prior regional
study [22], but incorporating eLearning modules similar to
those that have been previously shown to be successful in
changing clinician behaviours [26]. Each practice is asked to
nominate a representative from each staff discipline, e.g.
nurse, GP, pharmacist (in dispensing practices) and recep-
tionist (referred to collectively hereafter as ‘practice repre-
sentatives’). A dedicated member of the practice staff
(generally the practice asthma nurse) is then charged with
championing the intervention at the practice (referred to
hereafter as the practice champion) and ensuring dissemin-
ation via the practice representatives to maximise uptake.
Practice representatives receive a document describing the
purpose of the training and providing log-in details to the
eLearning training resource. The eLearning modules have
been developed in conjunction with Healthcare-Learning
(www.healthcare-learning.com). They are hosted on
the HealthCare-Learning secure website with links
from the Asthma UK Centre for Applied Research
website (www.aukcar.ac.uk). The main purpose of the
education is to advise all practice staff on actions to
take when presented with the electronic flag (see CDSS
below) on the EHRs of an at-risk patient. It comprises two
eLearning modules and a webinar:
(a) An individually completed module
This provides information on the national and patient per-
spectives of managing at-risk asthma, NRAD results [10],
findings from the studies that were precursors to the
ARRISA-UK study [21, 22], the flags to be added to patient
records and discipline-specific training as to suggested ac-
tions to be undertaken on seeing the flag. The training uses
a case scenario to highlight the possible benefits of the inter-
vention and self-assessments to permit active learning and
self-reflection. This module is to be undertaken by the
practice champion and representatives and takes up to
45 min to complete.
(b) A practice-representative team completed module
This module is organised and chaired by the practice
champion and attended by all of the practice representa-
tives. The purpose of this module is to permit represen-
tatives of the practice team to collectively reflect on the
material contained in the first module and encourage
practice staff to agree on and document how the inter-
vention will be implemented in their practice via a prac-
tice ‘action plan’. This covers the wording of the flag,
proposed actions of each staff discipline in response to
the flag, plans for including information in staff induc-
tion and disseminating to all staff, stance on informing
patients about their at-risk status and a method for com-
municating with out-of-hours services. This module
takes up to 45 min to complete
(c) A webinar
Ideally, within 8 weeks of completion of the second
module, the practice representatives are asked to dial into
a 30-min ‘webinar’ (online discussion) which reviews the
learning objectives and outcome from the modules. It per-
mits discussion within and between practices (in groups
of between two and eight practices) participating in the
study, allowing them to share experiences and ideas, and
refine their practice implementation and dissemination
plans accordingly. The webinars are being delivered by the
GP lead who originally implemented an at-risk asthma
register at his practice [21], developed and led the
face-to-face training in the prior study [22], and was
involved in developing the eLearning modules
3. CDSS
The CDSS consists of a flag which appears on the EHR
whenever a patient on the at-risk asthma register makes
contact with any member of the practice team and the clin-
ical record is opened, and is designed to prompt actions as
per the practice’s ‘action plan’ (see above). The nature of the
flag is dependent on the software used to manage the prac-
tice’s EHRs and varies between pop-ups that actively need
clearing from screen to yellow Post-it style notes remaining
on screen. ARRISA is compatible with the Vision (In Prac-
tice Systems Ltd., London, UK), EMIS (EMIS Health, Leeds,
UK) and SystmOne (The Phoenix Partnership (TPP), Leeds,
UK) EHRs which account for more than 90% of primary
care practices in the UK. The wording of the flag is chosen
by the practice during the second training module but
suggested wording of ‘At-Risk Asthma Prioritise Care’ is
given. Instructions for generating the flag are provided to
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the practice manager/IT lead. The flagging goes live after
the completion of the minimum training as defined below
4. Practice support
The practice champion receives a phone call approxi-
mately 4 weeks (between 2 and 6 weeks) after the activation
of the flags to ensure that there are no technical or other
fundamental implementation issues. Practice representatives
receive emails containing links to brief videos at 6 weeks
and 6 months that remind practices of the purpose of the
study and the importance of targeting, prioritising access for,
engaging with, and effectively managing, patients with
at-risk asthma at every opportunity.
Study newsletters will be circulated to practice repre-
sentatives for the duration of the study. These provide
updates on study progress including number of recruited
sites, timelines, etc. In addition, practice staff have ac-
cess to a helpline manned by an un-blinded IT techni-
cian for help with technical issues regarding the software
for the duration of the study. The eLearning website
contains links to national guidelines and other resources.
Full practice engagement with the training is encour-
aged as the flag is only activated after the completion of
minimum training, which we define as at least one prac-
tice member completing both eLearning training modules.
If required, we will send reminders to all practice repre-
sentatives by email on two occasions then contact them
by phone to encourage completion of the training. Assess-
ment of engagement with the intervention will form part
of the process evaluation and include examination of
modifications to the register, uptake and completion of
the training and engagement with follow-up phone calls.
Control
Control practices produce an anonymised list of patients
who meet the definition of at-risk asthma from the algo-
rithm. They are given instructions and asked to enter a
research-relevant Read code onto patients’ EHRs so that
they can be identified for the purpose of data collection.
However, practice staff are blind to the names and details
of the patients on the list until the end of the study. The
practice representatives from the control practices will also
receive study newsletters for the duration of the study.
The control practices continue to provide their usual care.
This may vary between practices, but reflects the recom-
mendations of the BTS/SIGN British Asthma Guideline [7]
and NICE guidelines [25]. Primary care practices in England
and Wales are incentivised to provide care to BTS/SIGN
standards as defined by the Quality and Outcome Frame-
work (QOF) [27]. This recommends creating a register of all
patients with asthma and offering at least annual
practice-based asthma reviews (typically in nurse-led clinics).
Recognised management includes checking control of
asthma symptoms with the Royal College of Physicians’
three questions (RCP3Qs; i.e. difficulty sleeping, daytime
symptoms, interference with usual activities), checking
smoking status and offering cessation advice, assessing/
teaching inhaler technique, assessing and offering advice
on adherence, and delivering patient self-management
education which may include provision of action plans
and self-monitoring tools [28]. Follow-up in secondary
care outpatient clinics and use of emergency primary and
care services is available as usual for patients, if required.
After completion of the trial, control practice staff will
be permitted to undertake the eLearning training and
un-blind and modify the register in the same way as inter-
vention practices could at the beginning of the study.
Outcomes
Primary outcome
The percentage of at-risk patients with an asthma-related
(defined as asthma, mixed asthma/chronic obstructive
pulmonary disease (COPD) and/or mixed asthma/respira-
tory infections) crisis event – i.e. an A&E attendance,
hospitalisation or death – over 12 months.
Secondary outcomes
1. The time to first, and rate of, asthma-related crisis
event(s) (defined as above) for at-risk patients
2. The percentage of all registered asthma patients
with an asthma-related crisis event, their rate of,
and time to, first asthma-related crisis event(s) (as
above)
3. The percentage of at-risk and all registered asthma
patients with good control defined as answering ‘no’
to all of the RCP3Qs [29]
4. The percentage of at-risk and all registered asthma
patients requiring a hospital admission or dying for
any reason
5. The number of the following (per patient per year)
for both at-risk and all registered asthma patients:
(a) short-acting bronchodilator prescriptions issued
(b) prescriptions of systemic corticosteroids for asthma
attacks and antibiotic-treated lower respiratory tract
infections
(c) modifications of the prescription of asthma-related
medications to align more closely with current guide-
lines (e.g. increased use of inhaled corticosteroids)
(d) records of written personalised asthma action plans
and patient self-monitoring with peak flow diaries
(e) inhaler technique assessments recorded
(f ) smoking cessation advice or smoking cessation
medications given
(g) flu vaccinations
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(h) ‘did not attends’ at primary and secondary care
routine appointments
(i) adherence to medication determined from validated
computer-based calculations using prescription data
Health economic outcomes
6. The estimated (per patient) mean incremental cost
of the at-risk register compared with usual care
7. The incremental effect of the at-risk register, in terms
of the estimated (per patient) mean difference (between
arms) in the number of asthma crisis events
Process evaluation outcomes
The outcomes include quantitative and qualitative as-
sessments of the views of healthcare professionals and
patients, practice procedures and processes of care, staff
awareness and behaviours, and indicators of uptake,
implementation and engagement with the intervention.
The process evaluation will also explore how key inter-
mediary and primary and secondary outcomes (e.g.
asthma control) are affected by contextual characteristics
(e.g. practice characteristics), including identification of
factors that will improve effectiveness and sustainability
in practice.
Safety outcomes
There will be no documentation or reporting of non-ser-
ious adverse events. Deaths and hospitalisation are the pri-
mary effectiveness outcome and will not be reported as
safety measures. Practices will be asked to capture com-
plaints or important study-related adverse events by com-
pleting a complaints/adverse events form and forward it
to the Norwich Clinical Trials Unit (NCTU).
Data collection
Baseline characteristics and outcome data
All practices expressing interest in the study are asked
to complete an initial questionnaire to provide basic data
on practice characteristics.
All participating practices must agree to share their
practice EHRs with Optimum Patient Care (Cambridge,
UK). Obtaining data in this way not only permits linkage
to different databases (practice EHRs, Office for National
Statistics (ONS), Hospital Episode Statistics (HES)), but
also permits data capture without burdening the practice
or patients. All practices (control and intervention) are
asked to insert a specific Read code that cannot be read-
ily removed by practice staff into the EHRs of at-risk
asthma patients to denote inclusion in this study. This
will be used by data managers and statisticians to iden-
tify these patients and distinguish their data from other
patients with active asthma in the practice. For the pur-
poses of data collection, active asthma is defined using
the QOF criterion [27]: Read code for asthma diagnosis
plus asthma therapy in the past year, excluding those
coded as asthma resolved but not excluding QOF excep-
tion codes. At the end of the study, data extractions will
be obtained for all patients with asthma in the practice
containing data for the 12 months before randomisation
and the 12 months following the activation of the flag in
the intervention practices. The mean time from random-
isation to activation of the flag will be calculated for all
intervention practices, and data collection will be cap-
tured for 12 months from this time after randomisation
in the control practices. For clinical event data and for
patients’ demographic and other characteristics (weight,
height, smoking status, etc.) the last recorded value will
be obtained.
Health economic data
Resources associated with establishing the at-risk regis-
ter, training, the CDSS and practice support will be esti-
mated from questionnaires and data obtained from the
training website. Additionally, details of patients’ NHS
resource use will be extracted from routinely recorded
data, where this will include all contacts with health pro-
fessionals and hospital admissions and asthma-related
medications.
Process evaluation data
Data captured from the training website for the purpose
of process evaluation include module completion rates,
time taken to undertake the training, time that the
training took place, the number of ‘hits’ on the website
resource pages, and changes in knowledge, attitudes
and motivation during the training as indicated by
self-assessment answers. Likewise, data collected from
the helplines and phone calls to practices conducted
between 2 and 6 weeks capture details of problems
with the intervention and practice engagement. Dur-
ing the second training module, practice teams will
be asked to complete online action plans, and these
will be captured along with notes from the webinar
facilitator, and recordings of webinars to assess details
of, and variation in, practice-level dissemination and
implementation of the intervention.
After the training, all practice representatives from
intervention practices are asked to complete an online
questionnaire to provide feedback regarding their experi-
ences and the perceived impact of the training and flags.
This will supplement the data captured by the training
software and assess the acceptability of the intervention,
further changes in knowledge, attitudes and motivation,
etc. over time and potential mechanisms by which the
training and flags may impact on processes of care. At
the end of the study all practice representatives from the
intervention practices will be asked to complete a further
online questionnaire to provide information regarding
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their experience of the intervention and its integration
into routine practice. ARRISA-UK practice champions
from intervention practices and practice contacts from
control practices will also be asked questions about major
changes in practice asthma management policies over the
preceding 12 months.
Taking a sequential, explanatory approach, findings
from analyses of preliminary quantitative data will be
used to inform sampling and topic guides for focus
groups and interviews with relevant stakeholders to-
wards the end of the study. These will explore, in more
depth, causal mechanisms, impacts and any unintended
consequences of the intervention, the acceptability of
the intervention and contextual factors affecting imple-
mentation. It is anticipated that dual moderator focus
groups [30] or interviews, will be undertaken with repre-
sentatives from at least six practice/staff group teams
(approximately eight participants per focus group) across
several study regions. Practice staff and patients at par-
ticipating practices will be identified and approached via
the practice champion. Both patients and practice staff
will be consented by process evaluation researchers prior
to being involved in focus groups and/or qualitative in-
terviews. A maximum diversity sample of participants
will be recruited to reflect a range of engagement with
the intervention/training and practice and staff charac-
teristics, guided by quantitative data if this identifies is-
sues for particular staff groups or types of practice. Each
focus group will last approximately 1 h and will be digit-
ally audio-recorded, then transcribed verbatim. A further
three focus groups, using the same methodology, will be
undertaken with patients from three of the practices rep-
resented in staff focus groups. The purpose of these
focus groups will be to explore patients’ experiences
and perspectives on the strengths and limitations of
‘at-risk’ registers and their potential for impact on pa-
tients’ asthma management. Fewer focus groups and
interviews will be undertaken if data saturation be-
comes apparent. Information from early focus groups
or interviews may also inform refinements to the
end-of-study questionnaires used to collect quantita-
tive data on the consequences and integration of the
intervention into routine practice from across a broad
range of practices.
Data management
Anonymised outcome and healthcare resource use data
will be received from Optimum Patient Care (routine
primary care data), the Healthcare-Learning eLearning
module database (training data), questionnaires and
transcripts of focus groups and interviews. These will be
uploaded onto a central study database stored on the
servers based at University of East Anglia (UEA). The
database will be password protected and only accessible
to members of the ARRISA-UK trial team at NCTU,
external regulators and process evaluation teams. The
server is in a secure room, which is protected by
closed-circuit television, where access is restricted to
members of the UEA Information Systems team by se-
curity door access. The study database has been built
using Microsoft Structured Query Language (SQL)
Server tools and all Internet traffic is encrypted via an
Hypertext Transfer Protocol Secure (HTTPS) connec-
tion, using Transport Layer Security (TLS) v1.2 and RSA
4096.u. periodically and at database lock the data will be
checked for errors and inconsistencies. The database is
designed to comply with the principles of the Inter-
national Conference on Harmonisation (ICH) Good
Clinical Practice (GCP), within the Standard Operating
Procedures (SOP) for Data Management in NCTU and
also where appropriate with UEA IT procedures. The
database and coding values have been developed by the
Head of Data Management in conjunction with the
study statistician and other NCTU members.
Sample size
A total sample size of 8204 patients from 235 practices
will provide 90% power to detect a difference in the
primary outcome (asthma crisis events) from 7% to 5%
(effect size of 0.3) assuming a cluster size of 35 and
intraclass correlation coefficient (ICC) of 0.01. These
estimates are from the event rate and prevalence of pre-
dicted hospitalisations and A&E attendance, as a whole
and per practice, obtained from a database of 48,000 pa-
tients obtained from Optimum Patient Care, and the
cluster size and ICC from our regional trial [22]. The
average cluster size was estimated from CRNs. Patients
will, as noted above, only be removed from the register
in exceptional circumstances and we estimate that less
than 10% of patients will leave their practice [31]. There-
fore, we planned to evaluate a total of approximately
9170 patients with at-risk asthma from 262 practices.
However, the initial average cluster size (39 patients per
cluster) was greater than estimated and we propose to
increase the sample size to 270 practices with 10,530
patients. If more than 10% of practices do not undergo
minimum training and flagging, additional practices
will be recruited. A decision to stop the study will be
considered if the power of the study is reduced to less
than 80% or when more than 30% of practices fail to
undergo training to a minimal degree and/or do not
activate the flag.
Randomisation
Practices will be randomised to the intervention or con-
trol, in a 1:1 ratio, based on a computer-generated ran-
domisation code, prepared by the study statistician, with
Smith et al. Trials  (2018) 19:466 Page 9 of 14
stratification for practice software (Vision/EMIS/Syst-
mOne) and presence of an asthma-diploma-trained
nurse at the practice (yes/no) at randomisation. Emails
are sent to practice managers and practice champions
informing them of their allocation with appropriate
log-in details for the study website and, for the interven-
tion practice, the eLearning modules.
Blinding
This pragmatic cluster randomised controlled trial is
being conducted with blind assessment and analysis of
outcomes. The practices (clusters) cannot be blind to
the intervention. The patients with asthma may or not
be blind to the intervention depending on whether indi-
vidual practices decide to inform patients they are on an
‘at-risk’ register. As far as possible, those researchers not
interacting with the practice sites will remain blind
throughout the study and analysis. The statistical ana-
lysis team will be blind to the intervention throughout.
The health economists will be blind during their initial
determination of costs and until that point in the ana-
lysis plan where they must include costs associated with
the allocation. The researchers implementing the inter-
vention, including the primary care physician leading the
webinar training programme, the qualitative interview
and focus group researchers and the research trial staff
providing assistance on practice sign up, follow-up
phone calls and providing support for the software, are,
of necessity, aware of allocation.
Analysis
Effectiveness analyses
The primary comparison of treatment arms at 12 months
will be based on the intention-to-treat (ITT) principle
including all patients initially identified with ‘at-risk’
asthma using the risk algorithm. The primary outcome
will be analysed on an individual-level using a logistic
regression model with random effects to allow for the
clustering of patients by practice and fixed effect for the
factors included in the stratification, i.e. practice soft-
ware and practice diploma-trained nurse. A similar
model will be used for the number of events, based on a
Poisson regression model with random and fixed effects,
and the time until the first event. Secondary outcomes
will be analysed in a similar fashion, which is to say that
the binary outcomes will be analysed using logistic re-
gression models and all count outcomes using Poisson
regression. All model assumptions will be assessed using
appropriate techniques and for Poisson regression
models over dispersion will also be checked.
Additional subgroup analyses
As well as the above ITT analyses (of data from patients
on the register at the time of randomisation) some
further pre-planned analyses will be conducted. In par-
ticular: (1) restriction of the analyses to only those pa-
tients who remain on the register over the course of the
year (unless removed due to death); (2) restriction of the
analysis to those intervention practices where all staff
representatives completed over 80% of the training; and
(3) inclusion of those individuals subsequently added to
the ‘at-risk’ register by the practice.
Health economic analyses
In line with the primary analysis, the health economic
base-case analysis will be conducted on an ITT basis.
Appropriate unit costs [32] will be assigned to each item
of resource use for a standard price year. The incremen-
tal cost of the at-risk register compared with standard
NHS care without an at-risk register, over the 12-month
trial period, will then be estimated by comparing the
mean overall cost (to the NHS) in each arm of the study
(with adjustment for other factors, e.g. clustering). Simi-
larly, the incremental effect will be estimated by compar-
ing the mean number of asthma crisis events between
arms. Additionally, based on data from other sources,
we will attempt to assign an estimated loss in quality of
life to each asthma-related crisis event, in order to
enable the incremental effect to also be estimated in
terms of Quality-adjusted Life Years (QALYs).
The incremental cost and incremental effect will sub-
sequently be used to estimate the cost-effectiveness of
the at-risk register. If dominance occurs, where the
at-risk register is both associated with a lower (higher)
cost and is more (less) effective, then the at-risk register
would be estimated to be cost-effective (or not). Alterna-
tively, the incremental cost-effectiveness ratio (ICER)
[33] will be estimated by dividing the incremental cost
by the incremental effect, where this will be compared
to any relevant thresholds, e.g. [34] in order to assess
value for money.
Non-parametric bootstrapping will be used to explore
the level of uncertainty surrounding the cost-effectiveness
results, and to construct cost-effectiveness acceptability
curves [35]. Sensitivity analysis [33] will also be under-
taken to assess the robustness of conclusions to changes in
key assumptions, including the aforementioned additional
analyses.
Process evaluation analyses
A comprehensive, mixed-methods process evaluation in
line with the Medical Research Council (MRC) guidance
[36], a published framework on the conduct of process
evaluation alongside cluster trials [37] and initial logic
model of the intervention (Fig. 3) will be undertaken.
Using the mixed-methods sequential explanatory ap-
proach [38], descriptive summaries of initial quantitative
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data will inform the focus of later qualitative research,
and any novel findings from the qualitative research will
generate further hypotheses for exploration with ana-
lyses of quantitative data where possible. The influence
of selected moderating contextual factors (e.g. practice
characteristics) on intermediary (e.g. process of care)
and clinical outcomes (e.g. crisis events, asthma control)
will be explored using regression models. Regression
models may also be used in mediation analyses to assess
potential mechanisms of the intervention.
Analyses of qualitative data from focus groups and inter-
views will be undertaken using Framework Analysis [39]
and supported by use of NVivo 9.0 software. At least two
project team members will analyse each transcript to en-
hance rigour. Efforts will be made to integrate qualitative
and quantitative process evaluation and outcome data
where possible to provide triangulation and aid interpret-
ation of findings, e.g. using matrix approaches.
Ethical issues and oversight
The study is being conducted in accordance with
CODEX rules and guidelines for research and the
Helsinki Declaration as well as the International Con-
ference on Harmonisation (ICH) Guideline for Good
Clinical Practice (GCP). The study protocol was approved
by North Wales Research Ethics Committee (reference
14/WA/1211) prior to the start of the study. The study is
registered on the International Standard Randomised
Controlled Trials Number (ISRCTN) registry (reference
ISRCTN95472706). Approval was granted by the Health
Research Authority (HRA) and Confirmation of Capacity
and Capability to conduct the study has been provided by
primary care R&D offices (including local CRN) and/or
individual practices as relevant.
Practices managers are asked to sign a contract with
UEA on behalf of all practice staff. Patients will not be
required to provide consent to use their data as their
extracted data are anonymised. Asthma is a common
condition and, therefore, patients are not potentially iden-
tifiable. All practices are asked to ensure that their patients
are aware (e.g. by displaying a poster, statements on web-
sites) that their data may be used anonymously for re-
search as this is standard procedure in research-ready
practices. The Read code identifying those patients that
are at-risk remains on the practice systems and only
Fig. 3 ARRISA-UK process evaluation logic model
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non-identifiable data will be extracted. Quotes from pa-
tients at focus groups or interviews that are published will
be anonymised. The focus group and interviews will not
be exploring highly sensitive issues and, therefore, the
study has no material ethical issues; however, individuals
participating in the focus groups or interviews will provide
written informed consent before participating.
UEA is the trial sponsor and has delegated responsibility
for the overall management of the trial to the chief investi-
gator and NCTU including the trial design, coordination,
monitoring and analysis and reporting of results. The
standard procedures and policies at NCTU, a UK Clinical
Research Collaboration (UKCRC)-registered trial unit and
the study’s Quality Management Monitoring Plan are
followed. A Trial Management Group (TMG) has been set
up to assist with the design, coordination and strategic
management of the trial. An independent Trial Steering
Committee (TSC) and independent Data Monitoring
Committee (DMC) have also been set up to provide over-
sight on all aspects of the trial and to safeguard the inter-
ests of primary care practices and patients, including
review of protocol amendments. Both the TMG and TSC
have lay membership.
Dissemination
We will publish the results of the study in peer-reviewed
journals and present the data at national and inter-
national conferences. Asthma UK, the Asthma UK
Centre for Applied Research (AUKCAR) and our hos-
pital and university media relations departments pledge
to support dissemination of the study outcomes with
coordinated press release and media coverage. We will
use the innovative dissemination channels of the AUK-
CAR (websites, public lectures and blogs) and the
co-applicants professional networks to ensure that find-
ings are both disseminated and adopted into practice if
the intervention is found to be effective. Asthma UK
will support dissemination to patients through their
network of volunteers and members, and to profes-
sionals via their Healthcare Professional Relationships
Manager.
Results will be reported following the use cluster exten-
sion to the Consolidated Standards of Reporting Trials
(CONSORT) and the REporting of studies Conducted
using Observational Routinely collected health Data
(RECORD) statements.
Discussion
This protocol describes a study that will explore the im-
pact of a primary care practice-wide intervention de-
signed to improve processes of care for at-risk asthma. It
is based on a previous regional study, with modifications
(automatic at-risk patient identification, online training
and remote anonymous data capture) which permit
large-scale implementation within a UK-wide multicen-
tre study across a large number of diverse practices.
Our intervention comprises automatic generation of a
list of people with at-risk asthma using a validated algo-
rithm based on data available from primary care EHRs
that are used by more than 90% of primary care prac-
tices in the UK. This permits standardised participant
identification throughout the country and also between
intervention and control practices. However we permit
modification of the list of at-risk patients for use by the
practice as we anticipate that clinical knowledge of their
patients will allow refinement of the list. In addition,
patients’ at-risk status is likely to change over time. We
have also automated the training aspect of the interven-
tion so that it is delivered via an online eLearning package
plus a webinar. This means that the intervention could be
rolled out throughout the UK and adopted into clinical
practice quickly if our intervention is deemed beneficial.
In this respect, a primary-care-based intervention, which
included education and asthma-nurse-led patient reviews
with an emphasis on self-management plans, has previ-
ously been shown to increase in the time to first attend-
ance with acute asthma from 126 to 194 days (HR 0.73
(0.54–1)) [40], as do interventions which utilise a practice
champion [40–42]. Our intervention is encouraged by a
practice champion and individuals are reminded of the
training via videos sent at 6 weeks and 6 months and also
every time the flag appears.
We have designed the ARRISA-UK CDSS to maxi-
mise its impact. The CDSS is a single flag which ap-
pears automatically whenever the patients’ EHRs are
opened (and is, therefore, timely) and it cannot be
readily switched off by practice staff (it is, therefore,
inescapable). The precise nature of the flag varies
somewhat between practice software (which is one of
the reasons that the study is stratified for practice
software) and varies from a pop-up box to one that
has to be cleared before any further action can be
taken. The wording of the flag is agreed by the prac-
tice representatives at the second eLearning module
(the group-based session where practice-wide action
plans are agreed) and can be changed during the
study, if required. The flag is designed to prompt ac-
tions as agreed in the practice action plan dissemi-
nated to all staff, so allows tailoring to practices’
existing processes of care.
The data required for the primary and secondary care
outcomes will be obtained from anonymous extraction
of routine healthcare data, without obtaining individual
informed consent as has been the case in similar studies
[22, 26, 31, 43]. However, we ask all practices to inform
patients that their data may be used anonymously for re-
search and practice managers will be asked to sign a
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contract with UEA on behalf of all practice staff. Written
informed consent will be obtained from patients to par-
ticipate in focus groups or interviews. We believe that
this meets ethical standards as the intervention is at
practice level and it is the practice staff/infrastructure
that are directly involved, not the patients. The Read
code identifying patients remains on the practice sys-
tems and only non-identifiable data will be extracted.
The data extraction methods meet all legal requirements
(http://optimumpatientcare.org/about-us/) and using an-
onymous patient data in this way is a recognised strategy to
improve patient care in line with the government agenda
including the care.data initiative (http://www.england.nh-
s.uk/ourwork/tsd/care-data/).
Trial status
The current version of the protocol is version 1.2, 4
February 2018. The trial began in August 2015 and we
expect to complete recruitment in April 2018.
Additional file
Additional file 1: Standard Protocol Items; Recommendations for
Interventional Trials (SPIRIT) 2013 Checklist: recommended items to
address in a clinical trial protocol and related documents. (DOC 121 kb)
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